Subtopic Deep Dive

Rapamycin Analogs and Resistance Mechanisms
Research Guide

What is Rapamycin Analogs and Resistance Mechanisms?

Rapamycin analogs are allosteric mTORC1 inhibitors like everolimus that face resistance through AKT reactivation and 4EBP1 mutations, prompting development of ATP-competitive inhibitors such as torin1.

Rapamycin analogs selectively inhibit mTORC1 but spare mTORC2, leading to feedback activation of upstream PI3K/AKT signaling (O’Reilly et al., 2006, 2531 citations). ATP-competitive mTOR inhibitors like torin1 overcome rapamycin resistance by targeting both mTORC1 and mTORC2 (Thoreen et al., 2009, 1778 citations). Over 20 papers in the provided list address mTOR inhibition mechanisms in cancer contexts.

Curated Papers

Key Challenges

Why It Matters

Rapamycin analogs like everolimus show clinical efficacy in renal cell carcinoma but resistance limits durable responses, as mTORC1 inhibition induces receptor tyrosine kinase signaling and AKT activation (O’Reilly et al., 2006). ATP-competitive inhibitors reveal rapamycin-resistant mTORC1 functions essential for tumor survival (Thoreen et al., 2009). These insights guide combination therapies targeting PI3K/AKT/mTOR pathway nodes in solid tumors (Glaviano et al., 2023).

Key Research Challenges

Feedback AKT Reactivation

Rapamycin induces upstream receptor tyrosine kinase signaling, activating AKT and limiting antitumor efficacy (O’Reilly et al., 2006, 2531 citations). This feedback loop sustains PI3K/AKT/mTOR signaling despite mTORC1 inhibition. Combination strategies with AKT inhibitors are explored to block this resistance.

Rapamycin-Resistant mTORC1 Functions

Allosteric inhibitors fail to suppress certain mTORC1 substrates like 4EBP1, allowing persistent translation (Thoreen et al., 2009, 1778 citations). ATP-competitive agents like torin1 fully inhibit these functions. Mutations in 4EBP1 further confer resistance in tumors.

mTORC1/2 Dual Inhibition Toxicity

ATP-competitive inhibitors target both complexes but cause hyperglycemia and immunosuppression (Hay and Sonenberg, 2004). Balancing efficacy against toxicity remains unresolved. Selective mTORC1 modulation strategies are under investigation.

Essential Papers

Upstream and downstream of mTOR

Nissim Hay, Nahum Sonenberg · 2004 · Genes & Development · 4.2K citations

The evolutionarily conserved checkpoint protein kinase, TOR (target of rapamycin), has emerged as a major effector of cell growth and proliferation via the regulation of protein synthesis. Work in ...

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · 2006 · Cancer Research · 2.5K citations

Abstract Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR...

mTOR signaling at a glance

Mathieu Laplante, David M. Sabatini · 2009 · Journal of Cell Science · 2.1K citations

The mammalian target of rapamycin (mTOR) signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation and su...

mTOR: a pharmacologic target for autophagy regulation

Young Chul Kim, Kun‐Liang Guan · 2015 · Journal of Clinical Investigation · 2.0K citations

mTOR, a serine/threonine kinase, is a master regulator of cellular metabolism. mTOR regulates cell growth and proliferation in response to a wide range of cues, and its signaling pathway is deregul...

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Carson C. Thoreen, Seong A. Kang, Jae Won Chang et al. · 2009 · Journal of Biological Chemistry · 1.8K citations

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

Sung Hee Um, Francesca Frigerio, Mitsuhiro Watanabe et al. · 2004 · Nature · 1.6K citations

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Antonino Glaviano, Aaron Song Chuan Foo, Hiu Yan Lam et al. · 2023 · Molecular Cancer · 1.6K citations

Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth...

Reading Guide

Foundational Papers

Start with Hay and Sonenberg (2004, 4173 citations) for mTOR pathway overview, then O’Reilly et al. (2006, 2531 citations) for resistance mechanisms, and Thoreen et al. (2009, 1778 citations) for ATP-competitive solutions.

Recent Advances

Study Glaviano et al. (2023, 1583 citations) for clinical translation of PI3K/AKT/mTOR inhibitors and He et al. (2021, 1575 citations) for targeted therapy advances.

Core Methods

Allosteric inhibition (rapamycin analogs), ATP-competitive inhibition (torin1), Western blot for p-AKT/p-4EBP1, cell viability assays for resistance profiling.

How PapersFlow Helps You Research Rapamycin Analogs and Resistance Mechanisms

Discover & Search

Research Agent uses searchPapers('rapamycin resistance AKT torin1') to find O’Reilly et al. (2006), then citationGraph to map 2531 citing papers on feedback mechanisms, and findSimilarPapers to uncover everolimus trials in renal cell carcinoma.

Analyze & Verify

Analysis Agent applies readPaperContent on Thoreen et al. (2009) to extract torin1 IC50 data, verifyResponse with CoVe to confirm rapamycin-resistant 4EBP1 phosphorylation, and runPythonAnalysis to plot dose-response curves from extracted figures using matplotlib.

Synthesize & Write

Synthesis Agent detects gaps in 4EBP1 mutation studies across papers, flags contradictions between allosteric vs. ATP-competitive efficacy; Writing Agent uses latexEditText for pathway diagrams, latexSyncCitations for 10+ references, and latexCompile for publication-ready review sections.

Use Cases

"Extract and plot mTOR inhibition IC50 values from torin1 vs rapamycin papers"

Research Agent → searchPapers('torin1 rapamycin IC50') → Analysis Agent → readPaperContent(Thoreen 2009) → runPythonAnalysis(pandas plot of dose-response curves) → matplotlib figure of comparative efficacy.

"Write LaTeX review section on AKT feedback resistance with citations"

Synthesis Agent → gap detection in resistance mechanisms → Writing Agent → latexEditText('feedback loop diagram') → latexSyncCitations(O’Reilly 2006, Hay 2004) → latexCompile → PDF section with mTOR pathway figure.

"Find GitHub repos analyzing everolimus resistance datasets"

Research Agent → searchPapers('everolimus resistance datasets') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis(reproduce RNA-seq analysis on resistance mutations).

Automated Workflows

Deep Research workflow scans 50+ mTOR papers via searchPapers → citationGraph → structured report on analog resistance evolution (Hay 2004 to Glaviano 2023). DeepScan applies 7-step CoVe analysis to O’Reilly (2006) abstracts, verifying AKT reactivation claims with GRADE scoring. Theorizer generates hypotheses on 4EBP1 mutation prevalence from Thoreen (2009) and similar papers.

Try Doxa for Rapamycin Analogs and Resistance Mechanisms Research

Frequently Asked Questions

What defines rapamycin analogs?

Rapamycin analogs like everolimus are allosteric mTORC1 inhibitors that bind FKBP12-rapamycin-binding domain, sparing mTORC2 (Laplante and Sabatini, 2009).

What are primary resistance mechanisms?

Resistance arises from AKT reactivation via upstream RTK signaling (O’Reilly et al., 2006) and incomplete 4EBP1 inhibition (Thoreen et al., 2009).

Which are key papers?

Foundational: Hay and Sonenberg (2004, 4173 citations) on mTOR regulation; O’Reilly et al. (2006, 2531 citations) on AKT feedback; Thoreen et al. (2009, 1778 citations) on ATP-competitive inhibitors.

What open problems exist?

Overcoming 4EBP1 mutation resistance and reducing dual mTORC1/2 inhibition toxicity without losing efficacy (Thoreen et al., 2009; Hay and Sonenberg, 2004).